Switch to:

Key Ratios

New Key Statistics Module, Z-Score and F-Score
Market Cap $M1,688Revenue (TTM) $M469Net Margin (%)13.2Altman Z-Score7.8
Enterprise Value $M1,615EPS (TTM) $1.9Operating Margin %21.9Piotroski F-Score7
P/E(ttm)28.2Beneish M-Score-2.9Pre-tax Margin (%)21.9Higher ROA y-yN
Price/Book4.710-y EBITDA Growth Rate %8.0Quick Ratio1.8Cash flow > EarningsY
Price/Sales3.75-y EBITDA Growth Rate %18.4Current Ratio3.7Lower Leverage y-yY
Price/Free Cash Flow31.8y-y EBITDA Growth Rate %18.9ROA % (ttm)11.7Higher Current Ratio y-yY
Dividend Yield %--PEG1.4ROE % (ttm)18.8Less Shares Outstanding y-yN
Payout Ratio %--Shares Outstanding M32.2ROIC % (ttm)24.3Gross Margin Increase y-yY

Gurus Latest Trades with CBM

Number of guru portfolios checked: 68.
TickerGuruDate Action
Impactdown Price Range
Current Price Change from Average Comment Current Shares
CBMThird Avenue Management 2016-09-30 Add0.01%$42.83 - $58.85
$ 52.508%Add 9.47%83,939
CBMThird Avenue Management 2016-03-31 Buy 0.13%$31.12 - $47.09
$ 52.5033%New holding76,681
CBMJoel Greenblatt 2016-03-31 Sold Out -0.06%$31.12 - $47.09
$ 52.5033%Sold Out0
CBMJoel Greenblatt 2015-12-31 Reduce-0.01%$40.43 - $53.63
$ 52.509%Reduce -19.35%110,565
CBMJoel Greenblatt 2015-09-30 Reduce-0.05%$39.57 - $53.82
$ 52.5012%Reduce -48.98%137,090
CBMJoel Greenblatt 2015-06-30 Add0.08%$35.71 - $46.24
$ 52.5027%Add 341.54%268,701
CBMJoel Greenblatt 2015-03-31 Reduce$21.34 - $39.63
$ 52.5078%Reduce -22.55%60,855
CBMJoel Greenblatt 2014-12-31 Buy 0.01%$16.33 - $24.12
$ 52.50147%New holding78,575
CBMJoel Greenblatt 2013-03-31 Sold Out -0.09%$11.27 - $12.79
$ 52.50340%Sold Out0
CBMJoel Greenblatt 2012-12-31 Buy 0.09%$9.34 - $13.96
$ 52.50361%New holding142,352
CBMJoel Greenblatt 2012-09-30 Sold Out -0.02%$9.01 - $13.01
$ 52.50375%Sold Out0
CBMJoel Greenblatt 2012-06-30 Buy 0.02%$5.96 - $9.16
$ 52.50643%New holding30,208
Premium Real Time Picks are included for Premium Members only!!
*The price and date might not be the actual time and price at which the transactions were made. In the case of institutional owners, the date is stated as the last day of their fiscal quarter. The prices are estimates if no accurate information available. Foreign holdings may not be included.

CBM is held by these investors:

Premium Most recent portfolio changes are included for Premium Members only!

CBM: Insider Buys/Sells

Click Here for All Insider Trades.
InsiderPosition Date Trades Shares Trade Price ($) Change (%) Details
SARGEN GREGORYExecutive Vice President & CFO 2016-11-11Sell22,500$52.020.92view
KLOSK STEVEN MPresident & CEO 2016-11-09Sell50,000$50.873.2view
KORB WILLIAM BDirector 2016-07-11Sell3,420$55-4.55view
KORB WILLIAM BDirector 2016-06-08Sell4,142$52.470.06view
KORB WILLIAM BDirector 2016-06-01Sell8,000$51.062.82view
KLOSK STEVEN MPresident & CEO 2016-05-09Sell14,005$497.14view
KLOSK STEVEN MPresident & CEO 2016-05-05Sell16,430$49.136.86view
KORB WILLIAM BDirector 2016-05-03Sell8,000$49.096.95view
KLOSK STEVEN MPresident & CEO 2016-03-16Sell19,565$4128.05view
Grabowsky Louis J.Director 2016-03-15Buy750$40.130.92view

Quarterly/Annual Reports about CBM:

News about CBM:

Articles On GuruFocus.com
Third Avenue Comments on Cambrex Corp May 27 2016 
Chip Rewey's Third Avenue Small-Cap Value Fund 2nd Quarter Commentary May 27 2016 
Royce Smaller-Companies Growth Fund Annual Letter Mar 19 2016 
Royce Smaller-Companies Growth Fund Shareholder Letter Sep 20 2015 
Cambrex Corp. Reports Operating Results (10-Q) Aug 04 2010 
Cambrex Corp. Reports Operating Results (10-Q) May 05 2010 
Does Cambrex Corporation Have Earnings Persistence? Apr 28 2010 
Cambrex Corp. Reports Operating Results (10-Q) Nov 04 2009 

More From Other Websites
Endo (ENDP) Inks Deal to Return Belbuca Rights to BioDelivery Dec 09 2016
Why Syndax Pharmaceuticals (SNDX) Could Be Positioned for a Slump Dec 09 2016
Zacks.com featured highlights: Big 5 Sporting Goods, Cambrex and Children's Place Dec 07 2016
Zacks.com featured highlights: Stamps.com, Gibraltar Industries, FutureFuel and Cambrex Dec 07 2016
AstraZeneca (AZN) Presents Tagrisso Data at Medical Meeting Dec 07 2016
Sage Therapeutics Stock Up on SAGE-547 Regulatory Update Dec 07 2016
Juno Reports Positive Phase I Study Data on Lymphoma Drug Dec 06 2016
Novo Nordisk Files Regulatory Application for Semaglutide Dec 06 2016
Alnylam Reports Positive Data on Fitusiran, Givosiran Dec 05 2016
Pfizer (PFE) Presents Favorable Data on Leukemia Candidate Dec 05 2016
Incyte Jakafi Positive in Pooled Analysis of Five-Year Data Dec 05 2016
Merck KGaA (MKGAF) Expands Distribution Deal with Roche Dec 02 2016
AbbVie Crohn's Disease Drug Gets Orphan Drug Status in U.S. Dec 01 2016
Agenus' INCAGN1876 in Phase I/II Study for Solid Tumors Dec 01 2016
CAMBREX CORP Financials Nov 30 2016
Novo Nordisk's Tresiba Shows Safe Cardiovascular Profile Nov 30 2016
Zacks.com featured highlights: Forestar Real Estate Group, McDermott International, Coherent,... Nov 30 2016
Zacks.com featured highlights: Alliance Resource Partners, EnerSys, Cambrex and Children's Place Nov 29 2016
Zacks.com featured highlights: Edgewell Personal Care, Cambrex, Humana, Research Frontiers and... Nov 29 2016
Hedge Funds Are Buying Cambrex Corporation (CBM) Nov 28 2016

Add Notes, Comments

If you want to ask a question or report a bug, please create a support ticket.
Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)